Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 25INDUSTRY 9NIH 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 25Rectal Neoplasms 21Colonic Neoplasms 11Esophageal Neoplasms 6Stomach Neoplasms 5Neoplasm Metastasis 5Adenocarcinoma Of Esophagus 5Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms 2Rhabdoid Tumor 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Metastatic Pancreatic Adenocarcinoma 1Medulloblastoma 1Lung Neoplasms 1Hepatoblastoma 1Gastrointestinal Neoplasms 1Gastro Oesophageal Cancer 1Fibrolamellar hepatocellular carcinoma 1Familial ependymoma 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Large Cell 1Breast Neoplasms 1

Interventions

Gemcitabine 10Cisplatin 7S 1 (combination) 6titanium silicide 2Oxaliplatin 2spartalizumab 1pembrolizumab 1pamiparib 1atezolizumab 1World Health Organization oral rehydration solution 1Temozolomide 1Paclitaxel 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Biliary Tract Neoplasms × Oxaliplatin × Clear all
NCT04796454 2022-06-01

PAMICC

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn
Gastrointestinal

Biliary Tract Neoplasms

NCT01234051 2011-12-12

Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer

Korean South West Oncology Group

Phase 2 Unknown
53 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡